相关实验视频

Updated: Jul 12, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

在实验性关节炎中,注入sivelestat载入纳米细胞的酶向输送抑制了关节炎的严重程度

Akshay Vyawahare¹, Md Meraj Ansari², Ajay Kumar¹

¹Department of Chemical Biology, Institute of Nano Science and Technology, Sector 81, Knowledge city, Sahibzada Ajit Singh Nagar, Mohali, Punjab 140306, India.

|October 25, 2023

概括

这项研究开发了载有sivelestat的双向纳米细胞,用于治疗类风湿性关节炎 (RA). 该疗法通过抑制关键酶有效降低了炎症并保护了软骨,为RA提供了有前途的新疗法.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
类风湿病学类风湿病学

背景情况:

类风湿性关节炎 (RA) 是一种慢性炎症性关节疾病,会导致严重的损伤.
像MMP-2和中性蛋白弹性酶 (NE) 这样的蛋白质酶会加剧RA的进展.
需要有针对性的药物输送系统来有效管理RA.

研究的目的:

为了合成和评估双酶向的毒素结合的纳米细胞载有sivelestat (SLM) 用于RA治疗.
评估SLM在原诱导性关节炎 (CIA) 鼠标模型中的体外和体内疗效.

主要方法:

毒素与纳米细胞结合,并将sivelestat纳入,以创建SLM.
SLM的特点是尺寸,药物负载,封装效率和体外细胞相容性.
在CIA老鼠模型中评估了活体抗关节炎潜力,评估了软骨完整性和酶表达.

主要成果:

SLM 呈现球形形态 (190-230 nm),具有良好的药物加载和封装效率.
在健康细胞系中没有观察到细胞毒性.
在体内实验中,研究表明CIA大鼠具有显著的胆固醇保护,恢复软骨完整性,并减少了促炎酶的表达.
SLM有效地抑制了突炎症的媒介和负责关节损伤的蛋白质酶.

结论:

通过纳米细胞进行双酶向和sivelestat输送,可显著缓解RA中的炎症.
同时抑制蛋白解酶提供了增强的冠状动脉保护和RA管理的潜力.
这种方法为风湿性关节炎提供了一个有前途的广泛治疗策略.

关键词:

关节软骨是一种关节软骨.骨损伤骨损伤骨损伤毒素是一种毒素.炎症炎症是一种炎症.纳米微粒是什么意思类风湿性关节炎类风湿性关节炎类风湿性关节炎

更多相关视频

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...